Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04949932
Other study ID # HUBREC/2021/09/02
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 3, 2021
Est. completion date May 12, 2021

Study information

Verified date July 2021
Source Hamdard University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Acne is a common problem in adolescence to young adult. But there is no such remedy available for acne treatment which has no side effects. Different types of herbs powder has been using in patients with acne vulgaris in the traditional practice of Indian subcontinent as single form or compound. Scientific evidence have shown many herbs has no known side effects and effective on acne. These herbs have antibacterial, anti-inflammatory and anti-oxidant effects. So, This study is intended to find out an inexpensive and safe alternative by using some common herbs such as Azadirachta indica, Curcuma longa, Lens culinaris Mentha arvensis and Trigonella foenum-graecum. The aim of the study is to evaluate the clinical efficacy of Poly herbal powder (PHP) for treating patients with acne vulgaris. Total of 42 adults with acne vulgaris was recruited for this study. Study subjects was included both of male and female with age limit of 18 to 35 years. Duration of study is 05 months with "day one advertisement" for screening followed by randomization for the treatment. The duration of active participation of each study subject was 3 consecutive weeks or 21days. Difference of baseline and post intervention mean by Total lesion Count (TLC) compared with placebo and assesses the % of reduction of acne based on The Global Acne Grading System (GAGS) score. Safety assessment was obtained from the incidence and type of adverse events during study period.


Description:

Background: Due to increasing interest from acne patients concerned about the side effects associated with conventional therapies, complementary and alternative medicine (CAM) has been suggested as a new therapeutic modality for acne vulgaris. Herbal medicine is one of these CAM treatments. Different types of herbs powder has been using in patients with acne vulgaris in the traditional practice of Indian subcontinent as single form or compound. As for example, Azadirachta indica, Curcuma longa, Ocimum sanctum, Lens culinaris, Trigonella foenum-graecum and Mentha arvensis etc. These herbs have antibacterial, anti-inflammatory and anti-oxidant effects. Therefore, this study was designed to evaluate the efficacy of poly-herbal powder (PHP) for treating acne vulgaris using some of these plants. Objective: To evaluate the clinical efficacy of PHP compared with that of placebo (PBO) in patients with acne vulgaris. Sample Size: Literature review have shown that sample size were included 20, 40, 75 and 503 study subjects in various research for treating acne vulgaris. Prior study has shown that the mean±SD of acne vulgaris at the baseline was 19.66 ±3.93 and after intervention it was 14.33±5.96 according to GAGS. Based on this results, the estimated enrollment of 15 per treatment group among those with acne vulgaris would provide the study with a statistical power of 80% (α = 0.05) and Confidence interval of 95% to detect the significant efficacy in acne. By using OpenEpi online calculator, required sample size is 30. But possibility of loss to follow up the inflated sample size is 42. Methods: For study subjects recruitment, advertisement was posted on online social networking platforms (such as facebook, Facebook Messenger, facebook groups, linkedIn, what's up and e-mail). The all relevant study requirements was included in the advertisement following a link of Google Form Questionnaire (socio-demographic data, specially instructed photograph) to participate in this study. Enrollment of respondent was done by acne lesions counting from the photograph sent by the study subjects through Google Form following fulfillment of inclusion criteria. Thereafter, Study subject was assigned to either PHP or PBO randomly for 03 consecutive weeks and intervention products was sent by courier according to study subject's present address. After intervention period study subjects was had to fill another Google Form Questionnaire including socio-demographic data, specially instructed photograph and other information. (Instructions for Taking Photograph: Mobile phone with camera, camera resolution must be 8 or more than 8 Mega pixels. Study subject has to take photo from a distance of 12 inches from face. Upload total of 6 photos (Right sided 2 photos, Left sided 2 photos and 2 photos from front) of face.) An intention-to-treat analysis will be conducted for patients who have received intervention at least once. Data will be presented as mean±SD and percentage of reduction in the change of counting acne lesions with 95% confidence interval and p=0.05. Efficacy Assessment: Difference of baseline and post intervention mean by Total lesion Count (TLC) compared with placebo and assesses the % of reduction of acne based on GAGS score. Difference between two means will be compared with independent two sample t-test. The Global Acne Grading System (GAGS): The GAGS is a quantitative scoring system to assess acne severity. It was first developed by Doshi and colleagues in 1997. The total severity score is derived from summation of six regional sub scores. Each is derived by multiplying the factors-2 for forehead, 2 for each check, 1 for nose, 1 for chin, 3 for both chest and back by the most heavily weighted lesion within each region (1 for ≥ one comedone, 2 for ≥ one papule,3 for ≥ one pustule, and 4 for ≥ one nodule). The regional factors were derived from consideration of surface area and distribution and density of pilosebaceous units. The summation of local score indicates, "0 = None, 1-18 = Mild, 19-30 = Moderate, 31-38 = Severe, > 39 = Very severe." Data and Safety Monitoring: To maintain the quality of this trial, data & safety monitoring will be conducted by Data & Safety Monitoring Board (DSMB). The members of the DSMB was included that individual who was not involved directly in this research. For this clinical trial, DSMB members was joined from the Faculty of Unani and Ayurvedic Medicine of Hamdard University Bangladesh (HUB). Safety assessment was obtained from the incidence and type of adverse events during study period.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date May 12, 2021
Est. primary completion date April 15, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: - Men and women both aged between 18-35 years - Presenting minimum 5 acne lesions (whiteheads, blackheads, papules, pustules, nodules) - Study subject who will be agreed with Online informed consent. Exclusion Criteria: - Have infected acne lesions - If study subject suffers from any serious medical conditions such as uncontrolled hypertension, diabetes mellitus, past or current malignancy, liver or kidney dysfunction, active pulmonary tuberculosis other severe dermatitis, or any infectious or systemic diseases. - Use of a topical medication containing steroids for the treatment of skin disease more than once per month. - Hypersensitive skin. - Erythema, or telangiectasia at the test site. - Use of the same or similar cosmetics (or pharmaceutical) on the test site within three months of screening. - Having undergone a skin peeling or having wrinkles removed within six months. - Any other reasons of unsuitability for the clinical trial at the discretion of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Mixed powder of Lens culinaris, Curcuma longa, Mentha arvensis, Azadirachta indica, and Trigonella foenumgraecum.
Study subjects were prescribed either PHP or placebo once daily at night for 3 weeks consecutively. A dose of 1-2 tea spoonfuls powder had to mixed with water to make paste. Then it was applied on face (except around the eyes) and had to wait for 20-30 minutes until it dries.Then they were washed face by using normal water.
Cicer arietinum powder
Study subjects were prescribed either PHP or placebo once daily at night for 3 weeks consecutively. A dose of 1-2 tea spoonfuls powder had to mixed with water to make paste. Then it was applied on face (except around the eyes) and had to wait for 20-30 minutes until it dries.Then they were washed face by using normal water.

Locations

Country Name City State
Bangladesh Hamdard University Bangladesh Munshiganj

Sponsors (1)

Lead Sponsor Collaborator
Dr. Md. Shahab Uddin

Country where clinical trial is conducted

Bangladesh, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Total Lesions Count (TLC) Total Lesions Count (TLC) = Comedones + Papules + Pastules, before and after intervention will be presented as percentage as well as mean and standard deviation. 03 weeks
Secondary Change in The Global Acne Grading System score The total severity score is derived from summation of six regional (i.e forehead, check, nose, chin, chest and back) sub scores. The summation of local score indicates, "0 = None, 1-18 = Mild, 19-30 = Moderate, 31-38 = Severe, > 39 = Very severe." 03 weeks
Secondary Change in non-inflammatory and inflammatory lesions count Pre and post treatment changes in non-inflammatory ( i.e Comedones) and inflammatory (i.e papule, pustule & nodule) acne lesions count will be presented as percentage as well as mean and standard deviation. 03 weeks
See also
  Status Clinical Trial Phase
Completed NCT04321070 - Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris Phase 1
Recruiting NCT05755256 - The Impact of Probiotics on Skin Hydration in Youth With Mild Acne Phase 2
Completed NCT05131373 - Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris Phase 1
Completed NCT01445301 - Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects Phase 3
Completed NCT03303170 - Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris N/A
Completed NCT04698239 - Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions. N/A
Completed NCT02886715 - A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris Phase 3
Terminated NCT02924428 - Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris N/A
Not yet recruiting NCT02491060 - A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris Phase 3
Not yet recruiting NCT02525822 - Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris Phase 2
Completed NCT02709902 - Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris Phase 1
Not yet recruiting NCT02535871 - A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris Phase 3
Completed NCT02250430 - A Phase 1 Study Assessing Local Cutaneous Effects of SB204 Phase 1
Completed NCT02913001 - The Effect of a Low Glycemic Load Diet on Hormonal Markers Associated With Acne N/A
Completed NCT01769664 - A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris Phase 1
Completed NCT01694810 - Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers Phase 1
Completed NCT01727440 - Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment N/A
Completed NCT01194375 - A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris Phase 2
Completed NCT02524665 - 8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne Phase 4
Completed NCT01706250 - U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™ Phase 4